IP Library Granted Patent US 7,317,016
Granted Patent B2
US 7,317,016 · App. 11/175,740 · Granted Jan 8, 2008

Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,317,016
App. No.
11/175,740
Granted
Jan 8, 2008
Kind
B2
Abstract

This invention relates to methods of treatment of cardiovascular disorders, thromboembolic disorders, inflammation, and disorders of the central nervous system using pyrazol pyridine derivatives of formula (I) wherein R 1 is a radical of the formula —O—SO 2 —R 3 in which R 3 is optionally substituted C 1-6 -alkyl, optionally substituted C 3-8 -cycloalkyl, or optionally substituted phenyl; R 2 is H, optionally substituted C 1-6 -alkyl-CO— or optionally substituted C 1-6 -alkyl-SO 2 —; as well as salts, stereoisomers, tautomers, and hydrates thereof.

Claims (12)

1. A method for inhibiting platelet aggregation in a subject in need thereof, comprising administering an effective amount of a compound of general-formula (I):

wherein

R 1 is a radical of the formula —O—SO 2 —R 3 , and

R 3 is a radical selected from the group consisting of optionally substituted C 1-6 -alkyl, optionally substituted C 3-8 -cycloalkyl, and optionally substituted phenyl;

and R 2 is H, optionally substituted C 1-6 -alkyl-CO or optionally substituted C 1-6 -alkyl-SO 2 —;

or a salt, stereoisomer, tautomer, or hydrate thereof.

2. A method of increasing coronary blood flow in a subject in need thereof, comprising administering an effective amount of a compound of general-formula (I):

wherein

R 1 is a radical of the formula —O—S 2 —R 3 , and

R 3 is a radical selected from the group consisting of optionally substituted C 1-6 -alkyl, optionally substituted C 3-8 -cycloalkyl, and optionally substituted phenyl;

and R 2 is H, optionally substituted C 1-6 -alkyl-CO or optionally substituted C 1-6 -alkyl-SO 2 —;

or a salt, stereoisomer, tautomer, or hydrate thereof.

Assignments (1)
MERGER Recorded Jan 12, 2010
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023769/0122 →